Sources: 
Sofinnova Partners, a veteran European venture capital firm with 50 years of experience backing over 500 companies, has partnered with NVIDIA to accelerate innovation in life sciences through advanced AI and computational power.
The collaboration provides significant Graphics Processing Unit (GPU) credits to select Sofinnova portfolio companies, granting them access to the same high-performance computing resources used by Silicon Valley tech giants.
One standout beneficiary, Cure51, a leader in cancer survivor biology, leveraged NVIDIA H100 GPUs to accelerate their genomics toolkit, achieving up to
17x faster processing and more than
2x cost savings compared to traditional CPU methods.
Antoine Papiernik, Chairman and Managing Partner at Sofinnova Partners, emphasized the strategic importance of this partnership:
"The convergence of biology, AI, computation, and data isn't just our investment thesis—it's the defining battleground of the next decade."This initiative aims to supercharge computational capabilities in life sciences, enabling faster, more cost-effective research and development, and positioning European biotech firms at the forefront of AI-driven innovation.
Founded in 1972, Sofinnova Partners' deep-rooted expertise combined with NVIDIA's cutting-edge GPU technology marks a significant step forward in the integration of AI and biology, promising transformative impacts on healthcare and life sciences.
Sources: Sofinnova Partners teams with NVIDIA to boost European life sciences innovation by providing GPU credits to portfolio companies, enabling faster, cost-efficient AI-driven research. Cure51 achieved 17x faster genomics processing and over 2x cost savings using NVIDIA H100 GPUs, marking a new AI frontier in biotech.
